Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans

Pancreatic ductal adenocarcinoma (PDAC) is currently the third leading cause of cancer mortality and the incidence is projected to increase by 2030. Despite recent advances in its treatment, African Americans have a 50-60% higher incidence and 30% higher mortality rate when compared to European Amer...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the National Medical Association 2023-04, Vol.115 (2), p.164-174
Hauptverfasser:	Telisnor, Guettchina, DeRemer, David L., Frimpong, Esther, Agyare, Edward, Allen, John, Ricks-Santi, Luisel, Han, Bo, George, Thomas, Rogers, Sherise C.
Format:	Artikel
Sprache:	eng
Schlagworte:	African Americans Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Black or African American - genetics Cancer therapies Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - ethnology Carcinoma, Pancreatic Ductal - genetics Carcinoma, Pancreatic Ductal - pathology Cytotoxicity Data analysis Diarrhea Disparities2 DNA repair DPD5 Enzymes Equity6 Genes Humans Kinases Medical prognosis Metabolism Molecular Targeted Therapy - methods Mutation Neutropenia Pancreatic cancer Pancreatic cancer3 Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - ethnology Pancreatic Neoplasms - genetics Pancreatic Neoplasms - pathology Pharmacogenetics Pharmacogenetics1 Toxicity UGT1A14
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!